Osaka-based drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with fellow Japanese firm PRISM BioLab. 29 April 2024
Long-term partners BioArctic and Eisai have announced a new research agreement regarding BAN2802, a potential treatment combining the former company’s proprieta 23 April 2024
Japanese drugmaker Astellas expects to book an impairment charge of 70 billion yen ($453 million) in the fourth quarter of Japan’s 2023 fiscal year, which ended 16 April 2024
Japanese conglomerate Fujifilm Holdings Corporation is to invest a further $1.2 billion to expand its large-scale cell culture CDMO business in North Carolina, 12 April 2024
Antibody drug conjugates (ADCs) are currently in vogue with investors and big pharma, as a rapidly emerging class of therapeutic agents that combine the target 10 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.